Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

Brenda D. Moore, Paramita Chakrabarty, Yona Levites, Tom L. Kukar, Ann Marie Baine, Tina Moroni, Thomas B. Ladd, Pritam Das, Dennis W Dickson, Todd E. Golde

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Introduction. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid (A) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe brains with plaque pathology similar in extent to AD, minimal cortical tau pathology, and no accompanying history of cognitive decline in the brain donor prior to death. PA may represent either a prodromal phase of AD, a benign form of A accumulation, or inherent individual resistance to the toxic effects of A accumulation. To attempt to distinguish between these possibilities we have systematically characterized A peptides in a postmortem series of PA, AD and non-demented control (NDC) brains. Methods. A was sequentially extracted with tris buffered saline (TBS), radioimmunoprecipitation buffer (RIPA), 2% sodium dodecyl sulfate (SDS) and 70% formic acid (FA) from the pre-frontal cortex of 16 AD, eight PA, and six NDC patients. These extracts were analyzed by 1) a panel of A sandwich ELISAs, 2) immunoprecipitation followed by mass spectrometry (IP/MS) and 3) western blotting. These studies enabled us to asses A levels and solubility, peptide profiles and oligomeric assemblies. Results: In almost all extracts (TBS, RIPA, 2% SDS and 70% FA) the average levels of A1-40, A1-42, A total, and Ax-42 were greatest in AD. On average, levels were slightly lower in PA, and there was extensive overlap between A levels in individual PA and AD cases. The profiles of A peptides detected using IP/MS techniques also showed extensive similarity between the PA and AD brain extracts. In select AD brain extracts, we detected more amino-terminally truncated A peptides compared to PA patients, but these peptides represented a minor portion of the A observed. No consistent differences in the A assemblies were observed by western blotting in the PA and AD groups. Conclusions: We found extensive overlap with only subtle quantitative differences between A levels, peptide profiles, solubility, and SDS-stable oligomeric assemblies in the PA and AD brains. These cross-sectional data indicate that A accumulation in PA and AD is remarkably similar. Such data would be consistent with PA representing a prodromal stage of AD or a resistance to the toxic effects of A.

Original languageEnglish (US)
Article number18
JournalAlzheimer's Research and Therapy
Volume4
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Alzheimer Disease
Peptides
Brain
formic acid
Sodium Dodecyl Sulfate
Poisons
Solubility
Buffers
Western Blotting
Pathology
Prodromal Symptoms
Equidae
Amyloid Plaques
Frontal Lobe
Immunoprecipitation
Amyloid
Mass Spectrometry
Enzyme-Linked Immunosorbent Assay
Tissue Donors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cognitive Neuroscience

Cite this

Moore, B. D., Chakrabarty, P., Levites, Y., Kukar, T. L., Baine, A. M., Moroni, T., ... Golde, T. E. (2012). Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. Alzheimer's Research and Therapy, 4(3), [18]. https://doi.org/10.1186/alzrt121

Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. / Moore, Brenda D.; Chakrabarty, Paramita; Levites, Yona; Kukar, Tom L.; Baine, Ann Marie; Moroni, Tina; Ladd, Thomas B.; Das, Pritam; Dickson, Dennis W; Golde, Todd E.

In: Alzheimer's Research and Therapy, Vol. 4, No. 3, 18, 2012.

Research output: Contribution to journalArticle

Moore, BD, Chakrabarty, P, Levites, Y, Kukar, TL, Baine, AM, Moroni, T, Ladd, TB, Das, P, Dickson, DW & Golde, TE 2012, 'Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains', Alzheimer's Research and Therapy, vol. 4, no. 3, 18. https://doi.org/10.1186/alzrt121
Moore, Brenda D. ; Chakrabarty, Paramita ; Levites, Yona ; Kukar, Tom L. ; Baine, Ann Marie ; Moroni, Tina ; Ladd, Thomas B. ; Das, Pritam ; Dickson, Dennis W ; Golde, Todd E. / Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. In: Alzheimer's Research and Therapy. 2012 ; Vol. 4, No. 3.
@article{877505eff13b4f96a4d5c5be76ac01cd,
title = "Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains",
abstract = "Introduction. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid (A) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe brains with plaque pathology similar in extent to AD, minimal cortical tau pathology, and no accompanying history of cognitive decline in the brain donor prior to death. PA may represent either a prodromal phase of AD, a benign form of A accumulation, or inherent individual resistance to the toxic effects of A accumulation. To attempt to distinguish between these possibilities we have systematically characterized A peptides in a postmortem series of PA, AD and non-demented control (NDC) brains. Methods. A was sequentially extracted with tris buffered saline (TBS), radioimmunoprecipitation buffer (RIPA), 2{\%} sodium dodecyl sulfate (SDS) and 70{\%} formic acid (FA) from the pre-frontal cortex of 16 AD, eight PA, and six NDC patients. These extracts were analyzed by 1) a panel of A sandwich ELISAs, 2) immunoprecipitation followed by mass spectrometry (IP/MS) and 3) western blotting. These studies enabled us to asses A levels and solubility, peptide profiles and oligomeric assemblies. Results: In almost all extracts (TBS, RIPA, 2{\%} SDS and 70{\%} FA) the average levels of A1-40, A1-42, A total, and Ax-42 were greatest in AD. On average, levels were slightly lower in PA, and there was extensive overlap between A levels in individual PA and AD cases. The profiles of A peptides detected using IP/MS techniques also showed extensive similarity between the PA and AD brain extracts. In select AD brain extracts, we detected more amino-terminally truncated A peptides compared to PA patients, but these peptides represented a minor portion of the A observed. No consistent differences in the A assemblies were observed by western blotting in the PA and AD groups. Conclusions: We found extensive overlap with only subtle quantitative differences between A levels, peptide profiles, solubility, and SDS-stable oligomeric assemblies in the PA and AD brains. These cross-sectional data indicate that A accumulation in PA and AD is remarkably similar. Such data would be consistent with PA representing a prodromal stage of AD or a resistance to the toxic effects of A.",
author = "Moore, {Brenda D.} and Paramita Chakrabarty and Yona Levites and Kukar, {Tom L.} and Baine, {Ann Marie} and Tina Moroni and Ladd, {Thomas B.} and Pritam Das and Dickson, {Dennis W} and Golde, {Todd E.}",
year = "2012",
doi = "10.1186/alzrt121",
language = "English (US)",
volume = "4",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

AU - Moore, Brenda D.

AU - Chakrabarty, Paramita

AU - Levites, Yona

AU - Kukar, Tom L.

AU - Baine, Ann Marie

AU - Moroni, Tina

AU - Ladd, Thomas B.

AU - Das, Pritam

AU - Dickson, Dennis W

AU - Golde, Todd E.

PY - 2012

Y1 - 2012

N2 - Introduction. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid (A) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe brains with plaque pathology similar in extent to AD, minimal cortical tau pathology, and no accompanying history of cognitive decline in the brain donor prior to death. PA may represent either a prodromal phase of AD, a benign form of A accumulation, or inherent individual resistance to the toxic effects of A accumulation. To attempt to distinguish between these possibilities we have systematically characterized A peptides in a postmortem series of PA, AD and non-demented control (NDC) brains. Methods. A was sequentially extracted with tris buffered saline (TBS), radioimmunoprecipitation buffer (RIPA), 2% sodium dodecyl sulfate (SDS) and 70% formic acid (FA) from the pre-frontal cortex of 16 AD, eight PA, and six NDC patients. These extracts were analyzed by 1) a panel of A sandwich ELISAs, 2) immunoprecipitation followed by mass spectrometry (IP/MS) and 3) western blotting. These studies enabled us to asses A levels and solubility, peptide profiles and oligomeric assemblies. Results: In almost all extracts (TBS, RIPA, 2% SDS and 70% FA) the average levels of A1-40, A1-42, A total, and Ax-42 were greatest in AD. On average, levels were slightly lower in PA, and there was extensive overlap between A levels in individual PA and AD cases. The profiles of A peptides detected using IP/MS techniques also showed extensive similarity between the PA and AD brain extracts. In select AD brain extracts, we detected more amino-terminally truncated A peptides compared to PA patients, but these peptides represented a minor portion of the A observed. No consistent differences in the A assemblies were observed by western blotting in the PA and AD groups. Conclusions: We found extensive overlap with only subtle quantitative differences between A levels, peptide profiles, solubility, and SDS-stable oligomeric assemblies in the PA and AD brains. These cross-sectional data indicate that A accumulation in PA and AD is remarkably similar. Such data would be consistent with PA representing a prodromal stage of AD or a resistance to the toxic effects of A.

AB - Introduction. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid (A) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe brains with plaque pathology similar in extent to AD, minimal cortical tau pathology, and no accompanying history of cognitive decline in the brain donor prior to death. PA may represent either a prodromal phase of AD, a benign form of A accumulation, or inherent individual resistance to the toxic effects of A accumulation. To attempt to distinguish between these possibilities we have systematically characterized A peptides in a postmortem series of PA, AD and non-demented control (NDC) brains. Methods. A was sequentially extracted with tris buffered saline (TBS), radioimmunoprecipitation buffer (RIPA), 2% sodium dodecyl sulfate (SDS) and 70% formic acid (FA) from the pre-frontal cortex of 16 AD, eight PA, and six NDC patients. These extracts were analyzed by 1) a panel of A sandwich ELISAs, 2) immunoprecipitation followed by mass spectrometry (IP/MS) and 3) western blotting. These studies enabled us to asses A levels and solubility, peptide profiles and oligomeric assemblies. Results: In almost all extracts (TBS, RIPA, 2% SDS and 70% FA) the average levels of A1-40, A1-42, A total, and Ax-42 were greatest in AD. On average, levels were slightly lower in PA, and there was extensive overlap between A levels in individual PA and AD cases. The profiles of A peptides detected using IP/MS techniques also showed extensive similarity between the PA and AD brain extracts. In select AD brain extracts, we detected more amino-terminally truncated A peptides compared to PA patients, but these peptides represented a minor portion of the A observed. No consistent differences in the A assemblies were observed by western blotting in the PA and AD groups. Conclusions: We found extensive overlap with only subtle quantitative differences between A levels, peptide profiles, solubility, and SDS-stable oligomeric assemblies in the PA and AD brains. These cross-sectional data indicate that A accumulation in PA and AD is remarkably similar. Such data would be consistent with PA representing a prodromal stage of AD or a resistance to the toxic effects of A.

UR - http://www.scopus.com/inward/record.url?scp=84861330645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861330645&partnerID=8YFLogxK

U2 - 10.1186/alzrt121

DO - 10.1186/alzrt121

M3 - Article

C2 - 22621179

AN - SCOPUS:84861330645

VL - 4

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 3

M1 - 18

ER -